<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01521832</url>
  </required_header>
  <id_info>
    <org_study_id>S015-001</org_study_id>
    <nct_id>NCT01521832</nct_id>
  </id_info>
  <brief_title>Escalating Dose Study in Healthy Volunteers With SEN0014196</brief_title>
  <official_title>A Phase I, Randomised, Double-Blind, Placebo-Controlled, Two-Part Study Consisting of Single and Multiple Oral Dose Escalation to Determine, Safety, Tolerability and Pharmacokinetics of SEN0014196</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Siena Biotech S.p.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Siena Biotech S.p.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a trial in healthy volunteers to study the safety, tolerability and pharmacokinetics&#xD;
      of single and multiple escalating doses of SEN0014196.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of ascending single and multiple oral doses of SEN0014196 in healthy male and female subjects.</measure>
    <time_frame>Up to 7 days after single dose and up to 10 days following multiple dose</time_frame>
    <description>Vital signs, cardiovascular and neurological function, laboratory safety parameters. Type and frequancy of adverse events.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Single and multiple dose pharmacokinetics of SEN0014196</measure>
    <time_frame>Up to 96 hours following single dose and up to 48 hours following multiple dose.</time_frame>
    <description>Basic pharmacokinetic parameters (Cmax, AUC, accumulation ratio, gender differences).</description>
  </secondary_outcome>
  <number_of_arms>11</number_of_arms>
  <enrollment type="Actual">88</enrollment>
  <condition>Huntington's Disease</condition>
  <arm_group>
    <arm_group_label>Dose Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Group C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Group D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Group E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Group F</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Group H</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Group I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Group J</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Group K</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Group L</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SEN0014196</intervention_name>
    <description>5 mg single oral dose</description>
    <arm_group_label>Dose Group A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SEN0014196</intervention_name>
    <description>25 mg single oral dose</description>
    <arm_group_label>Dose Group B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SEN0014196</intervention_name>
    <description>75 mg single oral dose</description>
    <arm_group_label>Dose Group C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SEN0014196</intervention_name>
    <description>150 mg single oral dose</description>
    <arm_group_label>Dose Group D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SEN0014196</intervention_name>
    <description>300 mg single oral dose</description>
    <arm_group_label>Dose Group E</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SEN0014196</intervention_name>
    <description>600 mg single oral dose</description>
    <arm_group_label>Dose Group F</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SEN0014196</intervention_name>
    <description>300 mg single oral dose (females)</description>
    <arm_group_label>Dose Group H</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SEN0014196</intervention_name>
    <description>100 mg multiple oral dose</description>
    <arm_group_label>Dose Group I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SEN0014196</intervention_name>
    <description>300 mg multiple oral dose</description>
    <arm_group_label>Dose Group J</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SEN0014196</intervention_name>
    <description>100 mg BID multiple oral dose</description>
    <arm_group_label>Dose Group K</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SEN0014196</intervention_name>
    <description>100 mg BID multiple oral dose (females)</description>
    <arm_group_label>Dose Group L</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects in Groups A to G and Groups I to K will be males of any ethnic origin between&#xD;
             18 and 55 years of age and with a body mass index (BMI) between 18 and 31 kg/m2&#xD;
             inclusive. Subjects in Groups H and L will be females of any ethnic origin between 18&#xD;
             and 65 years of age and with a body mass index (BMI) between 18 and 31 kg/m2&#xD;
             inclusive. All subjects will have a body weight greater than 50 kg. For Group H, women&#xD;
             will be of non-childbearing potential, defined as follows: Female subjects 50 years of&#xD;
             age or less must be surgically sterile or post-menopausal (defined as at least two&#xD;
             years post cessation of menses and/or follicular stimulating hormone &gt;18 mIU/mL and&#xD;
             serum oestradiol &lt;110 pmol/L), non-lactating and have a negative serum pregnancy test&#xD;
             Female subjects of more than 51 years of age must be surgically sterile or&#xD;
             post-menopausal (defined by a value of follicular stimulating hormone &gt;18 mIU/mL and&#xD;
             no spontaneous menstruation for at least one year before the first dose),&#xD;
             non-lactating and have a negative serum pregnancy test.&#xD;
&#xD;
          -  Subjects must be in good health, as determined by a medical history, physical&#xD;
             examination, 12-lead electrocardiogram (ECG) and clinical laboratory evaluations Note:&#xD;
             congenital non-haemolytic hyperbilirubinaemia is not acceptable and serum potassium&#xD;
             must be within the normal reference ranges (confirmed by repeat analysis).&#xD;
&#xD;
          -  Subjects will have given their written informed consent to participate in the study&#xD;
             and to abide by the study restrictions.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Male subjects or Female subjects in Group H who are not, or whose partners are not&#xD;
             willing to use appropriate contraception (such as condom) with spermicidal&#xD;
             foam/gel/film/cream/suppository) from the time of the first dose until 3 months after&#xD;
             the final dosing occasion. Female subjects in Group L who are not, willing to use&#xD;
             appropriate contraception (such as condom) with spermicidal&#xD;
             foam/gel/film/cream/suppository) from the time of screening until 3 months after the&#xD;
             final dosing occasion, who have not had a menstrual period in the 28 days before the&#xD;
             first dose.&#xD;
&#xD;
          -  Subjects who have received any prescribed systemic or topical medication within 14&#xD;
             days of the first dose administration (for female subjects, stable hormone replacement&#xD;
             therapy is acceptable) unless in the opinion of the Investigator the medication will&#xD;
             not interfere with the study procedures or compromise safety.&#xD;
&#xD;
          -  Subjects who have used any non-prescribed systemic or topical medication (including&#xD;
             herbal remedies) within 7 days of the first dose administration (with the exception of&#xD;
             vitamin/mineral supplements) unless in the opinion of the Investigator the medication&#xD;
             will not interfere with the study procedures or compromise safety.&#xD;
&#xD;
          -  Subjects who have received any medications, including St John's Wort, known to&#xD;
             chronically alter drug absorption or elimination processes within 30 days of the first&#xD;
             dose administration unless in the opinion of the Investigator the medication will not&#xD;
             interfere with the study procedures or compromise safety&#xD;
&#xD;
          -  Subjects who are still participating in a clinical study (e.g. attending follow-up&#xD;
             visits) or who have participated in a clinical study involving administration of an&#xD;
             investigational drug (new chemical entity) in the past 3 months, where possible this&#xD;
             will be confirmed using The Over Volunteering Protection Service (TOPS).&#xD;
&#xD;
          -  Subjects who have donated any blood, plasma or platelets in the 2 months prior to&#xD;
             screening or who have made donations on more than two occasions within the 12 months&#xD;
             preceding the first dose administration.&#xD;
&#xD;
          -  Subjects with a significant history of drug allergy as determined by the Investigator.&#xD;
&#xD;
          -  Subjects who have any clinically significant allergic disease (excluding non-active&#xD;
             hayfever) as determined by the Investigator.&#xD;
&#xD;
          -  Subjects who have a supine blood pressure and supine pulse rate higher than 140/90&#xD;
             mmHg and 100 beats per minute (bpm), respectively, or lower than 90/50 mmHg and 40&#xD;
             bpm, respectively, confirmed by a repeat assessment.&#xD;
&#xD;
          -  Subjects who consume more than 28 units (males) or more than 21 units (females) of&#xD;
             alcohol per week or who have a significant history of alcoholism or drug/chemical&#xD;
             abuse as determined by the Investigator (one unit of alcohol equals ½ pint [285 mL] of&#xD;
             beer or lager, one glass [125 mL] of wine, or 1/6 gill [25 mL] of spirits).&#xD;
&#xD;
          -  Subjects with a positive urine drug screen or alcohol breath test result at screening&#xD;
             or first admission. Or a history of substance abuse in the last 12 months prior to the&#xD;
             start of the study.&#xD;
&#xD;
          -  Subjects who smoke more than 5 cigarettes or the equivalent in tobacco per day.&#xD;
&#xD;
          -  Subjects with, or with a history of, any clinically significant neurological,&#xD;
             gastrointestinal, renal, hepatic, cardiovascular, psychiatric, respiratory, metabolic,&#xD;
             endocrine, haematological or other major disorders as determined by the Investigator.&#xD;
&#xD;
          -  Subjects with, or with a family history of Huntington's Disease&#xD;
&#xD;
          -  Subjects who have previously received histone deacetylase inhibitors e.g. vorinostat&#xD;
             (Zolinza®) or have participated in a clinical trial using a histone deacetylase&#xD;
             inhibitor.&#xD;
&#xD;
          -  Subjects who have had a clinically significant illness within 4 weeks of the start of&#xD;
             dose administration as determined by the Investigator&#xD;
&#xD;
          -  Subjects who are known to have serum hepatitis, or who are carriers of the hepatitis B&#xD;
             surface antigen (HBsAg) or hepatitis C antibody, or who have a positive result to the&#xD;
             test for HIV antibodies.&#xD;
&#xD;
          -  Subjects who have an abnormality in the 12-lead ECG that, in the opinion of the&#xD;
             investigator, increases the risk of participating in the study, such as QTcF interval&#xD;
             &gt;450 msec (male) or greater than 470msec (female), or with sinus rhythm with PR&#xD;
             interval &lt;110 msec or &gt;240 msec, confirmed by a repeat ECG.&#xD;
&#xD;
          -  Subjects who, in the opinion of the Investigator, should not participate in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph A Chiesa, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Covance</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Covance Clinical Research Unit</name>
      <address>
        <city>Leeds</city>
        <zip>LS2 9LH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>January 2012</verification_date>
  <study_first_submitted>January 13, 2012</study_first_submitted>
  <study_first_submitted_qc>January 30, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 31, 2012</study_first_posted>
  <last_update_submitted>February 6, 2012</last_update_submitted>
  <last_update_submitted_qc>February 6, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 7, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Huntington Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

